<code id='F469F32818'></code><style id='F469F32818'></style>
    • <acronym id='F469F32818'></acronym>
      <center id='F469F32818'><center id='F469F32818'><tfoot id='F469F32818'></tfoot></center><abbr id='F469F32818'><dir id='F469F32818'><tfoot id='F469F32818'></tfoot><noframes id='F469F32818'>

    • <optgroup id='F469F32818'><strike id='F469F32818'><sup id='F469F32818'></sup></strike><code id='F469F32818'></code></optgroup>
        1. <b id='F469F32818'><label id='F469F32818'><select id='F469F32818'><dt id='F469F32818'><span id='F469F32818'></span></dt></select></label></b><u id='F469F32818'></u>
          <i id='F469F32818'><strike id='F469F32818'><tt id='F469F32818'><pre id='F469F32818'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:4379
          om DiLenge (CQ in grey suit ) Flagship Pioneering Cambridge with US Congressman Raja Krishnamoorthi of Illinois were talking together at the event. Biotech companies demonstrating their medicines and materials at a "tech fair" designed to showcase the need to compete with Chinese biotech held at Harvard Kennedy School in Cambridge. The growing US backlash against the perceived national security threat posed by China's rising biotech industry
          Tom DiLenge of Flagship Pioneering (left) with U.S. Congressman Raja Krishnamoorthi of Illinois at a "tech fair" designed to showcase the need to compete with Chinese biotech held at Harvard Kennedy School in Cambridge, Mass. David L Ryan/The Boston Globe

          CAMBRIDGE, Mass. — The increasingly adversarial relationship between the United States and China has raised national security concerns about Chinese penetration into key sectors of the U.S. economy, such as technology, manufacturing, and clean energy.

          Now, some in Congress are raising alarms about China’s threat to another vital industry: biotechnology.

          advertisement

          A bipartisan group of lawmakers visited Massachusetts this week to call attention to that threat and call for strengthening U.S. life sciences companies, protecting their technologies, and safeguarding Americans’ genetic data from a Chinese biotech industry with close ties to the authoritarian state.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          FogPharma raises $145 million in rare Series E round
          FogPharma raises $145 million in rare Series E round

          FogPharmaCEOMathaiMammenBostonGlobePhotoImportOncologystartupFogPharmajustcloseda$145millionSeriesEr

          read more
          Continuity nursing helped my family in our darkest PICU moments
          Continuity nursing helped my family in our darkest PICU moments

          EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

          read more

          Bristol Myers buys into radiopharmaceuticals with RayzeBio

          CourtesyBristolMyersSquibbBristolMyersSquibbwillpay$4.1billionforRayzeBio,thecompaniessaidTuesday,bu